Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®
14 4월 2022 - 8:30PM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare
company, today announced Twirla prescription data for the first
quarter 2022.
During the first quarter 2022:
- Twirla cycles dispensed increased 29% to
16,602
- Total prescriptions (TRx) increased 27% to
12,494
- Refills (RRx) increased 31% to 7,143
- New prescriptions (NRx) increased 22% to
5,351
- Total prescribers increased 26% to 5,837
“As I said on our recent fourth quarter 2021 earnings call, we
believe we have a brand that is building steady growth momentum,
which we saw continue in the prescription demand data for the first
quarter 2022,” said Al Altomari, Agile Therapeutics Chairman and
Chief Executive Officer. “This growth is consistent with what we
reported for the fourth quarter 2021 and we continue to believe we
are seeing signs of a healthy, growing brand.”
“Our focus is on continued execution of the business plan we
have in place and building upon the momentum we established
throughout 2021 and into the first quarter 2022,” said Amy Welsh,
Agile Therapeutics Vice President of Marketing. “Our three key
initiatives – the Afaxys partnership, a focus on California through
Medi-Cal, and the Twirla Connected TV (CTV) commercial – were
deployed throughout the first quarter 2022 and all three are now
active as we enter the second quarter 2022. With each of the three
components of our business plan fully active, we believe growth in
Twirla demand can continue to build momentum throughout 2022.”
About Agile Therapeutics, Inc.Agile
Therapeutics is a women's healthcare company dedicated to
fulfilling the unmet health needs of today’s women. Our
product and product candidates are designed to provide women with
contraceptive options that offer freedom from taking a daily pill,
without committing to a longer-acting method. Our initial
product, Twirla®, (levonorgestrel and ethinyl estradiol), a
transdermal system, is a non-daily prescription contraceptive.
Twirla is based on our proprietary transdermal patch technology,
called Skinfusion®, which is designed to allow drug delivery
through the skin. For more information, please visit the company
website at www.agiletherapeutics.com. The
Company may occasionally disseminate material, nonpublic
information on the Company’s website.
About Prescription DataThe Company receives
prescription data for Twirla from Symphony Health Solutions, and
the data are not created or owned by the Company. Prescription data
are available through other subscription services as well, such as
IQVIA. The prescription data results reported in this press release
are reported as of April 13, 2022, by Symphony Health Solutions.
The prescription data terms are defined as follows: Twirla cycles
dispensed are the number of 3-patch packages dispensed. Each
3-patch package represents one 28-day cycle of therapy. Total
Cycles Dispensed represents every cycle dispensed from both retail
and non-retail channels. Retail channels include retail pharmacies,
mail order, and long-term care while non-retail channels include
clinics and hospitals and other entities where prescriptions are
dispensed directly to the patient. Total prescriptions (TRx) are
the total number of prescriptions dispensed through the retail
channels. This represents both new and refill prescriptions. New
prescriptions (NRx) are new prescriptions dispensed through retail
channels. Refill prescriptions (RRx) are refill prescriptions
filled through retail channels. Total prescribers are the
cumulative number of prescribers whose prescriptions were filled
through retail channels since launch.
Forward-Looking StatementCertain information
contained in this press release includes “forward-looking
statements”, within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, related to the Company’s financial status,
the growth of Twirla and the momentum of such growth, the success
of the Company’s key initiatives and their effect on the Company’s
results, and the execution of the Company’s commercial plan. We
may, in some cases use terms such as “predicts,” “believes,”
“potential,” “continue,” “anticipates,” “estimates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “likely,” “will,”
“should” or other words that convey uncertainty of the future
events or outcomes to identify these forward-looking statements.
Our forward-looking statements are based on current beliefs and
expectations of our management team that involve risks, potential
changes in circumstances, assumptions, and uncertainties, including
statements regarding the growth in prescriptions and demand for
Twirla, the execution of our commercial and business plan, and the
contribution of certain elements of our business plan to continued
growth in Twirla prescription demand. Any or all of the
forward-looking statements may turn out to be wrong or be affected
by inaccurate assumptions we might make or by known or unknown
risks and uncertainties. These forward-looking statements are
subject to risks and uncertainties including risks related to our
ability maintain regulatory approval of Twirla, our ability to
successfully commercialize Twirla, regulatory and legislative
developments in the United States and foreign countries,
our ability to obtain and maintain intellectual property protection
for Twirla, our strategy, business plans and focus, and the other
risks set forth in our filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K and
our Quarterly Reports on Form 10-Q. For all these reasons, actual
results and developments could be materially different from those
expressed in or implied by our forward-looking statements. You are
cautioned not to place undue reliance on these forward-looking
statements, which are made only as of the date of this press
release. We undertake no obligation to publicly update such
forward-looking statements to reflect subsequent events or
circumstances.
Contact:
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024